Fullbrook Thorpe Investments
Mercia Marina Findern Ln, Willington, Derbyshire, DE65 6DW, United Kingdom
Overview
Fullbrook Thorpe Investments is a private equity fund that invests both directly and as partners with other private equity businesses. It has formed valuable strategic alliances with several prominent private equity businesses such as LDC, Maven Capital Partners, and Yorkshire Fund Managers, as well as forming links with other family office investors. The company was founded in 2015 and is based in Willington, Derbyshire.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Karshare
Participated · Series A · Aug 2021
Karshare operates an on-demand peer-to-peer car-sharing platform that lets people rent their cars to others within their community. The service uses keyless technology so cars are instantly available and renters can book and access vehicles via the app without arranging key handovers. All cars on the platform are fully insured through the service and include breakdown cover. Led by founder Andy Hibbert, Karshare raised £3m in a Pre-Series A funding round. The company plans to use the funds to expand in existing locations including Bristol, Manchester, Coventry and London and to launch in Birmingham, Leeds, Edinburgh and rural communities such as Strathaven and Talybont. Karshare also intends to hire additional talent to grow its team.
- Atlantic Healthcare
Participated · Equity · Mar 2016
Atlantic Healthcare develops alicaforsen enema, an antisense oligonucleotide therapy targeting ICAM-1 for inflammatory bowel diseases, currently in Phase 3 for pouchitis. The company has initiated a pivotal Phase 3 trial recruiting 138 patients across 40 trial centres in the US, Canada, Europe and Israel, with results expected in H2 2017. Alicaforsen has FDA fast-track designation and FDA and EMA orphan drug designations in pouchitis, and Atlantic holds regulatory and patent exclusivity to circa 2030. The product is also ready to commence Phase 3 for acute distal ulcerative colitis and the company is preparing regulatory filings with the U.S. FDA, EMA and Health Canada. Alicaforsen is generating early revenues in Europe through Named Patient Supply protocols and LDC commented the business is already generating revenues. Prior Phase 2 studies involving 377 patients reportedly demonstrated reductions in inflammation and mucosal healing with good tolerability.